Search - tctmd.com

Displaying 41 - 60 of 89

Sort: Relevancy | Date

News Daily News

Little Pre- and Postmarket Testing for Most Recalled CV Devices

Michael O'Riordan

September 16, 2024

News Daily News

Evolut TAVI Shows Promise in Low-risk Bicuspid Patients at 3 Years

Yael L. Maxwell

July 22, 2024

News Daily News

Knowns and Unknowns in Subclinical Aortic Valve Thrombosis

Caitlin E. Cox

June 21, 2024

News Conference News NY Valves 2024

Bioprosthetic Valve Dysfunction Tied to Worse Outcomes After AVR

Todd Neale

June 14, 2024

Presentation NY Valves 2024

Mid-term Outcomes of Balloon Expandable TAVR for the Treatment of Failed Bioprosthetic Valves in the United States

Presenter: Tsuyoshi Kaneko

June 07, 2024

Presentation NY Valves 2024

Impact of Bioprosthetic Valve Performance on 5-year Clinical Outcomes in Patients at Intermediate or Greater Surgical Risk

Presenter: Steven J. Yakubov

June 07, 2024

Presentation NY Valves 2024

Prediction Models for the Treatment of Bioprosthetic Aortic Valve Failure in the United States

Presenter: Philippe Genereux

June 07, 2024

Presentation NY Valves 2024

ViV TMVR in a Patient With Torrential Bioprosthetic MR in Cardiogenic Shock

Presenter: Chloe Kharsa

June 07, 2024

Presentation NY Valves 2024

Halt is Not Relevant

Presenter: Stephan Windecker

June 06, 2024

Presentation NY Valves 2024

Halt is Relevant

Presenter: Raj Makkar

June 06, 2024

Presentation NY Valves 2024

Debate Con: Echo First and Only to Diagnose Bioprosthetic Valve Dysfunction /Failure

Presenter: Rebecca T. Hahn

June 06, 2024

Presentation NY Valves 2024

Debate Pro: Invasive Assessment is Mandatory to Confirm Bioprosthetic Valve Dysfunction /Failure

Presenter: David A. Wood

June 06, 2024

Presentation NY Valves 2024

Debate Con

Presenter: Amr E. Abbas

June 06, 2024

Presentation NY Valves 2024

Debate Pro

Presenter: Howard C. Herrmann

June 06, 2024

Presentation NY Valves 2024

Thromboaspiration of a Left-Sided Bioprosthetic Valve Thrombosis by a Mini-Invasive Access: A Novel Procedure to Alleviate the Risks of Thrombolysis, Angiovac and Redo-Surgery

Presenter: Ziyad Gunga

June 06, 2024

News Conference News NY Valves 2024

Long-term Mortality After TAVI Lower With DOACs vs VKAs

Todd Neale

June 06, 2024

Presentation NY Valves 2024

Which endpoints and definitions matter for assessment of bioprosthetic valve durability following TAVR?

Presenter: Philippe Pibarot

June 06, 2024

Presentation NY Valves 2024

Why Favor Redo SAVR After a Failed Bioprosthetic AVR?

Presenter: Tsuyoshi Kaneko

June 06, 2024

Presentation NY Valves 2024

You are Both Wrong, Engineers Hold the Key to Our Future and the Best Valve Design is Yet to be Found

Presenter: Ajit P. Yoganathan

June 06, 2024

Presentation NY Valves 2024

SAVR Will Have a Longer Lasting Durability Than TAVR

Presenter: Stephan Windecker

June 06, 2024

Advertisement

Little Pre- and Postmarket Testing for Most Recalled CV Devices

Evolut TAVI Shows Promise in Low-risk Bicuspid Patients at 3 Years

Knowns and Unknowns in Subclinical Aortic Valve Thrombosis

Bioprosthetic Valve Dysfunction Tied to Worse Outcomes After AVR

Mid-term Outcomes of Balloon Expandable TAVR for the Treatment of Failed Bioprosthetic Valves in the United States

Impact of Bioprosthetic Valve Performance on 5-year Clinical Outcomes in Patients at Intermediate or Greater Surgical Risk

Prediction Models for the Treatment of Bioprosthetic Aortic Valve Failure in the United States

ViV TMVR in a Patient With Torrential Bioprosthetic MR in Cardiogenic Shock

Halt is Not Relevant

Halt is Relevant

Debate Con: Echo First and Only to Diagnose Bioprosthetic Valve Dysfunction /Failure

Debate Pro: Invasive Assessment is Mandatory to Confirm Bioprosthetic Valve Dysfunction /Failure

Debate Con

Debate Pro

Thromboaspiration of a Left-Sided Bioprosthetic Valve Thrombosis by a Mini-Invasive Access: A Novel Procedure to Alleviate the Risks of Thrombolysis, Angiovac and Redo-Surgery

Long-term Mortality After TAVI Lower With DOACs vs VKAs

Which endpoints and definitions matter for assessment of bioprosthetic valve durability following TAVR?

Why Favor Redo SAVR After a Failed Bioprosthetic AVR?

You are Both Wrong, Engineers Hold the Key to Our Future and the Best Valve Design is Yet to be Found

SAVR Will Have a Longer Lasting Durability Than TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content